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Abstract
Background
The international public health (PH) community is debating the opportunity to incorporate
genomic technologies into PH practice. A survey was conducted to assess attitudes of the
European Public Health Association (EUPHA) members towards their role in the implemen-
tation of public health genomics (PHG), and their knowledge and attitudes towards genetic
testing and the delivery of genetic services.
Methods
EUPHA members were invited via monthly newsletter and e-mail to take part in an online
survey from February 2017 to January 2018. A descriptive analysis of knowledge and atti-
tudes was conducted, along with a univariate and multivariate analysis of their
determinants.
Results
Five hundred and two people completed the questionnaire, 17.9% were involved in PHG
activities. Only 28.9% correctly identified all medical conditions for which there is (or not) evi-
dence for implementing genetic testing; over 60% thought that investing in genomics may
divert economic resources from social and environmental determinants of health. The
majority agreed that PH professionals may play different roles in incorporating genomics
into their activities. Better knowledge was associated with positive attitudes towards the use
of genetic testing and the delivery of genetic services in PH (OR = 1.48; 95% CI 1.01–2.18).
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Conclusions
Our study revealed quite positive attitudes, but also a need to increase awareness on geno-
mics among European PH professionals. Those directly involved in PHG activities tend to
have a more positive attitude and better knowledge; however, gaps are also evident in this
group, suggesting the need to harmonize practice and encourage greater exchange of
knowledge among professionals.
1. Introduction
The development of precision medicine (PM, also referred to as “personalized medicine”) has
generated a debate within the international public health (PH) community on the opportunity
to use genetic information and genomic applications in preventive medicine. However, the
introduction of PM interventions into PH practice is still controversial. On one hand, the
more skeptical have argued that investing in genomics may divert resources away from basic
public health services and from addressing the structural causes of ill health [1–4]. On the
other hand, public health professionals and associations worldwide have stressed that the
potential of PM to identify high risk individuals and develop tailored preventive interventions
cannot be ignored [5–8].
Over recent decades, several professionals have supported the incorporation of genome-
based knowledge and technologies into PH, leading to the emergence of public health geno-
mics (PHG) as a multidisciplinary field promoting the appropriate translation of genomics
research into health benefits for individuals and populations [9,10]. PH professionals may play
different roles in this translation, from evaluating the effectiveness and cost-effectiveness of
genomic applications to modelling and assessing the implementation of evidence-based geno-
mic applications into medical practice [9]. One of the priorities of the PHG movement is to
achieve adequate knowledge and capacity among PH professionals to facilitate the integration
of genomic information into PH activities [11–15]. What is the current level of competence of
PH professionals in genomics? Several surveys have been performed to evaluate the knowl-
edge, attitudes and professional behavior of physicians towards the integration of human
genomic discoveries into clinical practice [16–21], but only one study targeted PH practition-
ers [22] and it focused solely on predictive genetic tests for chronic diseases. We conducted a
survey on a sample of European PH professionals belonging to the network of the European
Public Health Association (EUPHA), which represents European PH professionals, to assess
their attitudes towards their role in the implementation of PHG, and their knowledge and atti-
tudes regarding genetic testing and genetic services.
2. Material and methods
The study was conducted within the EU-funded project PRECeDI (Personalized PREvention
of Chronic DIseases).
A specific questionnaire was developed for the survey, consisting of 33 items grouped into
five sections (see S1 Text):
A. Professional details (four questions);
B. Professional activity (seven questions);
C. Knowledge of genetic testing and delivery of genetic services (four questions);
D. Attitudes towards genetic testing and delivery of genetic services (four questions);
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E. Attitudes towards the role of PH professionals in PHG (six questions).
“The development of the questionnaire was informed by a literature review and by similar
studies previously carried out by the same research group [18, 22]. It was also based on the
inputs received by the members of EUPHA Section on PHG and by all partners of PRECeDI
project, as described elsewhere [23]
“For the purpose of the survey, we defined genetic testing as “performing a type of medical
test involving an analysis of human chromosomes, DNA, RNA, genes, and/or gene products
(e.g., enzymes and other types of proteins), which is predominately used to detect heritable or
somatic mutations, genotypes, or phenotypes related to disease and health”, following the defi-
nition proposed by Burke [24]. Further to discussion with other PRECEDI project partners,
we have decided to adopt the classification of genetic testing used by the European Society of
Human Genetics [25]. In particular, the survey was aimed at investigating knowledge and atti-
tudes towards the implementation of susceptibility (also known as predisposition) tests,
defined as “the detection of genetic variants that are associated with an increased risk of disease
but cannot predict with certainty the development of disease, because of the incomplete pene-
trance of the genetic mutation”. Examples of this type of tests include BRCA testing, Lynch
syndrome testing and familial hypercholesterolemia genetics tests. A “genetic service” was
defined as “the provisions to diagnose, advise and treat individuals with risk factors for genetic
disorders.” According to our interpretation, the delivery of a genetic service is therefore
expected to provide not only genetic testing and counselling, but also treatment and follow up
of individuals with genetic disorders, similarly to what was previously described by Battista
et al.[26]. Statements included in section E were based on published literature dealing with the
relationship between public health and human genomics and the possible role of public health
professionals in putting PHG into practice [27] A filter question included in section B gave
access to an extended version of the questionnaire, including four additional items in both sec-
tions C and D, for professionals who answered that they were involved in PHG activities. A
pilot phase of the survey was conducted on 61 staff members of the Department of Public
Health and Infectious Diseases of Sapienza University in Rome and 10 members of the Depart-
ment of Genetics from the Vrije University in Amsterdam, to test clarity of language, practica-
bility and interpretation of answers. Internal consistency was also assessed by obtaining
Cronbach’s alpha coefficients. The questionnaire proved to be reliable in assessing attitudes
towards the role of PH professionals in PHG, and it was slightly revised before distribution to
the EUPHA network to improve the quality of some questions [23].
The questionnaire was administered online from March 2017 to February 2018. An invita-
tion to participate in the survey was included in the EUPHA monthly newsletter of February
2017; furthermore, the Presidents of five EUPHA sections (Public Health Genomics, Public
Health Epidemiology, Public Health Monitoring and Reporting, Public Health Practice and
Policy, Chronic Diseases) sent an invitation to their members to respond to the survey. A final
reminder was sent to all EUPHA members in September 2017. The first page of the survey
included a description of its objective and of the different section of the questionnaire, and
informed participants that all data collected were anonymous. Thus, no consent was requested
to participate in the survey. The Ethical Committee of Sapienza University of Rome granted its
approval to conduct the survey.
Survey responses were collected in an electronic spreadsheet (see S1 Dataset). A descriptive
analysis was performed to define the distribution of socio-demographic characteristics of the
sample and to assess rates of positive/negative attitudes towards and knowledge of PHG (fre-
quencies, percentages, mean values and SD were calculated). An analysis of determinants of
knowledge and attitudes on genetic testing and the delivery of genetic services, and on the
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roles of PH professionals in incorporating genomics into PH activities was conducted through
the construction of multiple logistic regression models. The variables “knowledge on PHG”,
“attitudes on PHG” and “attitudes on the role of PH professionals” originally consisting of
multiple categories, were collapsed into two levels, adapting the methodology previously used
in other surveys conducted by our research group [18, 22, 28]: a high level of knowledge of
PHG was attributed to respondents providing correct responses to at least three of four ques-
tions included in section C of the questionnaire; positive attitudes towards PHG were defined
as positive attitudes towards the three statements included in section D of questionnaire,
except for question D1, which was excluded because it showed a totally different trend in the
univariate analysis; for “attitudes on the role of PH professionals”, responders with positive
attitudes were those who agreed with all six statements included in section E. Covariates
included in the models were: group of professionals (involved in PHG activities vs not
involved), gender, age, history of genetic conditions, exposure to information on genetic test-
ing during undergraduate or post-graduate education, area of degree (with medicine as refer-
ence category), sector of work (with the academic sector chosen as reference), main area of
work.
Multiple logistic regression models were built using the strategy suggested by Hosmer and
Lemeshow [29]. Each variable was examined by univariate analysis using the appropriate sta-
tistical test (Student’s t-test or χ2 test) and was included in the model when the p-value was
less than 0.25. Subsequently, multivariate logistic regression with backward elimination of any
variable that did not contribute to the model on the grounds of the Likelihood Ratio test (cut-
off, p = 0.05) was performed. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated. All statistical calculations were performed using Stata version 15.0 (Stata Cor-
poration, College Station, TX, USA).
Approval to conduct the study was granted from the Ethics Committee of Sapienza Univer-
sity of Rome.
3. Results
Six hundred and twenty-two people accessed the survey and 502 completed all sections
(80.7%). Respondents came from all EU28 Countries and some non–EU Countries, including
Albania (n = 1), Andorra (n = 1), Bosnia and Herzegovina (n = 4), Norway (n = 15), Russia
(n = 1), Serbia (n = 3), Switzerland (n = 25), Turkey (n = 7), and there were 27 people working
in developing countries at the time the survey was conducted The response rate obtained was
approximately 10%. Table 1 summarizes the main socio-demographic characteristics of the
respondents. There were no significant differences in the socio-demographic characteristics
between people who completed the whole survey and those who did not, except for the area of
degree, with medical doctors being less likely to complete it (p = 0.026).
For knowledge of genetic testing, only 1.7% of respondents (9/526) correctly identified all
applications of genetic testing that are based (or not based) on evidence of effectiveness, while
26.1% correctly identified at least eight out of 10 (141/526), which we set as the threshold for a
correct response to this question (Table 2). Nearly 30% of respondents correctly identified all
clinical conditions for which there is (or is not) strong evidence supporting the use of a genetic
test (CDC tier-1) (Table 2). When asked about the professionals involved in the delivery of
genetic testing, nearly 50% of respondents (49.4%, 256/518) correctly indicated that such pro-
fessionals could equally be general practitioners or geneticists or oncologists (Table 2). Most
respondents (91.0%, 472/519) knew that predictive/predisposition genetic tests must be associ-
ated with genetic counseling (Table 2).
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In the subgroup analysis on PH professionals declaring an involvement in PHG activities,
only 12.1% of them (4/33) correctly indicated the number of clinical conditions with available
evidence supporting the implementation of a genetic test to predict disease risk, while 32.1%
(15/53) correctly identified all components of a genetic service; in particular, less than half of
respondents thought that treatment, follow-up and clinical surveillance can also be considered
within the components of a genetic service (respectively 37.7%, 49.1%, and 47.2%) (see Tables
2_bis in S1).
Most respondents showed positive attitudes towards the implementation of genetic testing
and the delivery of genetic services, except for the idea that it would be more important to
invest resources in the social and environmental causes of ill health than in the implementa-
tion of genetic testing, with over 60% of the sample agreeing with this statement (Table 3).
Positive attitudes were also reported in the extended version addressed to professionals
involved in PHG, ranging from 77.6% of respondents (38/49) indicating that the application of
Table 1. Socio-demographic characteristics of respondents.
CHARACTERISTICS N (%)
Gender (n = 593)�
Female 287 48.4
Male 306 51.6
Age (n = 591)�
25–40 197 33.3
41–55 219 37.1
56–75 175 29.6
Type of health professional (n = 576)�
PH professional not involved in PHG 440 76.4
PH professional involved in PHG 57 9.9
Not PH professional and not involved in PHG 27 4.7
Not PH professional but involved in PHG 52 9.0
Area of degree (n = 574)�
Medicine 295 51.4
Health professions (e.g nursing) 50 8.7
Biology 30 5.2
Public health 73 12.7
Other (e.g. statistics, political sciences) 126 21.9
Sector of work (n = 573)�
Academic 337 58.8
Hospital 28 4.9
Government (national or local) 113 19.7
Public health service 33 5.8
Other (e.g. NGO, technical agency) 62 10.8
Information on genetic screening in undergraduate training (n = 573)�
Yes 242 57.8
No 331 42.2
Information on genetic screening in postgraduate training (n = 574)�
Yes 245 42.7
No 278 48.4
Not applicable 51 8.9
�Number of respondents to the question.
https://doi.org/10.1371/journal.pone.0230749.t001
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Table 2. Knowledge of genetic testing and the delivery of genetic services, n (%).
Which of the following applications of genetic testing are based on evidence of effectiveness?
(multiple answers are possible) (n = 526)�a
No Yes
Diagnose disease 189
(35.9)
337
(64.1)
Determine the severity of a disease 420
(79.8)
106
(20.2)
Identify genetic mutations that are responsible for an already diagnosed disease 209
(39.7)
317
(60.3)
Identify genetic mutations that may increase the risk of developing a disease 139
(26.4)
387
(73.6)
Identify genetic mutations that could be passed on to children 163
(31.0)
363
(69.0)
Identify genetic mutations that influence the process of ageing 427
(81.2)
99 (18.8)
Guide doctors in deciding on the best treatment to use for certain individuals 276
(52.5)
250
(47.5)
Guide doctors in designing an optimal individualized weight loss diet 489
(93.0)
37 (7.0)
Ascertain the gender of a fetus 354
(67.3)
172
(32.7)
Screen newborn babies for certain treatable conditions 187
(35.6)
339
(64.4)
For which of the following clinical conditions is there currently a base of synthesized evidence
supporting the implementation of genetic testing to predict disease risk? (multiple answers are
possible) (n = 525)�b
No Yes
Hereditary ovarian cancer 138
(26.3)
387
(73.7)
Lynch syndrome (hereditary nonpolyposis colorectal cancer) 231
(44.0)
294
(56.0)
Gastric cancer 461
(87.8)
65 (12.2)
Metastatic non-small-cell lung cancer 470
(89.5)
55 (10.5)
Prostate cancer 452
(86.1)
73 (13.9)
Alzheimer’s disease 370
(70.5)
155
(29.5)
Familial hypercholesterolemia 264
(50.3)
261
(49.7)
Type 2 diabetes 413
(78.7)
112
(21.3)
Acute myeloid leukemia 447
(85.1)
78 (14.9)
Depression 487
(92.8)
38 (7.2)
Which of the following professionals may be involved in the delivery of genetic testing?(n = 509)�
A. General practitioner 9 (1.7)
B. Geneticist 61 (11.8)
C. Oncologist 9 (1.7)
D. All of the above 256
(49.4)
E. B+C 183
(35.3)
(Continued)
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genetic testing in healthy family members of individuals with hereditary chronic diseases may
increase prevention opportunities to 98.0% (48/49) agreeing (or strongly agreeing) that specific
training initiatives are needed for PH professionals to develop their capacity to evaluate the
quality of genetic services (see Tables 3_bis in S1).
There were high rates of agreement with the proposed roles that PH professionals may play
in putting PHG into practice (Table 3). In particular, percentages of agreement ranged from
88.4% of respondents (448/507) who agreed (or strongly agreed) that public health thinking
should consider that risk factors can affect subsets of the population differently based on
genetic susceptibility to 78.7% of respondents (399/507) who agreed (or strongly agreed) that
public health programs should actively implement genomic applications that are evidence-
based (e.g. BRCA testing for relatives of known mutation carriers) (Table 3).
Table 4 summarizes the results of the multivariate analysis. A high level of knowledge was
associated with indicating PHG as one of the main areas of work, having graduated in medi-
cine, having received training on genetic testing during undergraduate education and working
in a PH service. A high level of knowledge of genetic testing and genetic services was associated
with positive attitudes towards PHG, while academics were less likely to be positive on the
topic. People working directly in PHG were more likely to disagree with the importance of
investing resources in social and environmental causes of health rather than in genomics.
Finally, positive attitudes towards the role of PH professionals in implementing PHG were
associated with working in PHG and with having received information on PHG during under-
graduate training.
4. Discussion
This survey revealed poor knowledge of genetic testing and the delivery of genetic services in a
representative sample of European PH professionals. However, overall, attitudes towards both
the use of genetic testing and delivery of genetic services, and the involvement of PH profes-
sionals in putting PHG into practice, were positive. The only negative sentiment was in
response to the proposal that it was more important to invest resources in the social and envi-
ronmental causes of ill health than in the implementation of genetic testing. Over 60% of
respondents agreed in fact that public health resources should be targeted mainly at addressing
the structural causes of ill health.
Table 2. (Continued)
Which of the following applications of genetic testing are based on evidence of effectiveness?
(multiple answers are possible) (n = 526)�a
No Yes
Performing susceptibility (or predisposition) tests should necessarily be associated with genetic counseling that includes
information, informed consent, and discussion of the results (n = 519)�
Agree 472
(91.0)
Uncertain 35 (6.7)
Disagree 12 (2.3)
�Number of respondents to the question.
aA correct response to the question was defined as having correctly identified at least 8/10 applications of genetic
testing that are based (or not) on evidence of effectiveness.
bA correct response to the question was defined as having correctly identified all conditions for which there is (or is
not) currently evidence supporting the implementation of genetic testing.
Percentages referring to correct answers are in bold.
https://doi.org/10.1371/journal.pone.0230749.t002
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Nevertheless, over 70% of participants agreed that genetic tests for diseases that could have
a fatal outcome (e.g. BRCA testing for breast and ovarian cancer) should be provided free at
the point of delivery for those who could benefit from them. High rates of respondents also
thought that, in the future, PH programmes (e.g. cancer screening, chronic disease prevention
programmes) will make greater use of genetic information. Therefore, PH professionals seem
to agree in principle with the importance of including genomic applications in PH practice,
but at the same time they seem to fear that this could divert resources from addressing the “tra-
ditional” determinants of health. There is a long-standing debate in the PH community on the
opportunity to focus on -omics and personalized medicine, and whether this may divert from
the traditional population-based approach. However, the need to go beyond the dichotomous
high-risk versus population approach was suggested, taking into account that also precision
public health could contribute to improving population health and achieving social justice—
equity, social inclusion, and empowerment [5].
Given the cost constraints currently faced by European healthcare systems, some prioritiza-
tion criteria are needed to decide which genetic services should be funded from public budgets
[30], and these should include consideration of medical benefit, health needs and costs. In this
regard, a high proportion of respondents agreed with the idea that evidence on effectiveness
and cost-effectiveness should guide the decision of whether to introduce genetic and genomic
applications into clinical and PH practice. Such evidence is already robust for some genetic
tests of chronic clinical conditions, such as hereditary breast and ovarian cancer, Lynch syn-
drome and familial hypercholesterolemia [31–34]. However, according to the responses
recorded in our survey, many PH professionals are not fully aware of this: 26% for hereditary
breast/ovarian cancer, 44% for Lynch Syndrome and 50% for familial hypercholesterolemia
Table 3. Attitudes towards genetic testing and the delivery of genetic services, and towards the role of PH professionals in PHG (% of answers).
Statement Strongly
agree
Agree Neither agree nor
disagree
Disagree Strongly
disagree
It is more important to invest resources in the social and environmental causes of ill health than in
the implementation of genetic testing (n = 522)�
27.6% 32.8% 25.3% 13.2% 1.1%
Susceptibility (or predisposition) tests should be introduced in the clinical and public health
practice even without health interventions with proven efficacy (n = 522)�
3.0% 12.8% 10.0% 41.6% 32.6%
Susceptibility (or predisposition) tests should be introduced in the clinical and public health
practice only if economic evaluations show cost-effectiveness ratios favorable compared with
alternative health interventions (n = 522)�
14.2% 44.5% 18.8% 18.8% 3.6%
Genetic tests for diseases that could have a fatal outcome (e.g. BRCA testing for breast and ovarian
cancer) should be provided free at the point of delivery to people who could benefit from them
(n = 522)�
28.3% 43.7% 11.5% 12.3% 4.2%
Public health thinking should consider that risk factors can affect subsets of the population
differently based on genetic susceptibility. (n = 507)�
26.6% 61.7% 6.9% 3.8% 1.0%
Public health professionals should be involved in the continuous assessment of the utility and
validity of emerging genomic applications (n = 507)�
37.6% 52.3% 8.1% 1.8% 0.2%
Public health programs should actively implement genomic applications that are evidence-based
(e.g. BRCA testing for relatives of known mutation carriers). (n = 507)�
27.2% 51.5% 17.4% 3.7% 0.2%
Public health professionals should measure the utilization of genetic services in order to assess
unmet needs and inequalities of access to services (n = 507)�
29.9% 50.7% 14.8% 2.8% 1.8%
Public health professionals should measure in practice outcomes, process indicators and value
added of genomic applications (n = 507)�
34.4% 49.2% 13.8% 1.8% 0.8%
I think that in the future public health programmes (e.g. cancer screening, chronic diseases
prevention programmes) will make a greater use of genetic information. (n = 507)�
29.8% 55.6% 12.6% 1.8% 0.2%
�Number of respondents to the question.
Percentages referring to positive attitudes towards genetic testing and delivery of genetic services, and towards the proposed roles of PH professionals are in bold.
https://doi.org/10.1371/journal.pone.0230749.t003
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did not know that the evidence supported the implementation of the relative genetic testing to
predict disease risk for these conditions. More widespread knowledge of those genetic and
genomic applications with documented evidence of effectiveness and cost-effectiveness would
therefore probably improve attitudes towards both the inclusion of PM in preventive interven-
tions and the funding of such interventions through public budgets.
Another result that supports the thesis of improving knowledge to improve attitudes is the
association between agreement with investing resources in genomics and involvement in work
activities dealing with personalized medicine. This finding highlights the importance of
increasing awareness of the opportunities that PM can offer, particularly among PH profes-
sionals not directly involved in genomics projects and/or activities. Communication and train-
ing needs have been also identified as key challenges in the implementation of PM by the
European PerMed Consortium [35], while the PRECeDI consortiuum added among its rec-
ommendations the training of. of clinical and public health professionals should be promoted
with the aim of reducing inappropriate use in healthcare [36].
Although professionals involved in PHG activities are better informed about genetic testing,
gaps in knowledge were also identified in this group. This may be due to differences in recom-
mendations for use of genetic testing, to a lack of standard procedures for the evaluation of
genetic services, and to differences in how genetic services are delivered in different countries.
It has in fact been reported that, internationally, different frameworks are adopted for the eval-
uation of genetic testing [37]. Furthermore, organizations that develop guidelines on the
implementation of genomic medicine show wide variation in the use of external and system-
atic reviews, as well as in the updating of recommendations, when they are assessing the
strength of relevant scientific evidence [38]. At the European level, it has been emphasised that
Table 4. Multivariate analysis of determinants of knowledge and attitudes (only significant results shown).
Variables OR 95% CI P value
Model 1: Higher level of knowledge of genetic testing and the delivery of genetic servicesa
PHG as main area of work (0 = no, 1 = yes) 6.35 2.62–15.33 0.000
Information on PHG during undergraduate training (0 = no, 1 = yes) 1.53 1.02–2.30 0.040
Area of degree (0 = other, 1 = medicine) 1.77 1.16–2.69 0.007
Sector of work (0 = other, 1 = public health service) 1.98 1.05–3.73 0.000
Model 2: Positive attitudes towards genetic testing and delivery of genetic servicesb
Sector of work (0 = other, 1 = Academic) 0.67 0.47–0.97 0.032
Knowledge (0 = score� 2, 1 = score 3, 4 1.48 1.01–2.18 0.048
Model 3: Positive attitudes towards the use of resources for genetic testingc
PHG as main area of work (0 = no, 1 = yes) 9.10 3.95–20.94 0.000
Model 4: Positive attitudes towards the role of PH professionals in PHGd
PHG main area of work (0 = no, 1 = yes) 4.04 1.48–11.02 0.006
Information on genetic testing during undergraduate training (0 = no, 1 = yes) 1.74 1.21–2.48 0.003
a Respondents were classified as those who answered correctly to three out of four questions addressing knowledge of
genetic testing and the delivery of genetic services (Table 2) vs. all others.
b Respondents were classified as those who showed a positive attitude towards all the statements addressing attitudes
towards genetic testing (Table 3) except the first one, which was analyzed separately.
c Respondents were divided into those who declared they disagreed or strongly disagreed with the statement “It is
more important to invest resources in the social and environmental causes of ill health than in the implementation of
genetic testing”(value = 1) vs all others (value = 0).
d Respondents were classified as those who showed a positive attitude towards all the statements addressing the
possible role of PH professionals in implementing PHG vs all others.
https://doi.org/10.1371/journal.pone.0230749.t004
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guidelines and policies to support the integration of genomics policies into existing healthcare
systems need to be harmonized across countries [26,39]. It has also been highlighted that cur-
rent genetic services are usually delivered without an internationally standardized set of pro-
cess and outcome measures, making the evaluation of healthcare services difficult [40]. Only a
limited number of PHG professionals considered treatment, follow-up and clinical surveil-
lance to be a component of a genetic service. This may be due to differences in the organiza-
tional models of genetic services across countries: research on this topic has in fact shown that
the definition of a genetic service may vary largely across different settings [41–44].
There was strong agreement that PH professionals should foster the integration of geno-
mics into PH practices, and over 80% of respondents agreed that in the future PH programs
will make greater use of genetic information. Positive attitudes towards the involvement of PH
professionals in genomics were associated with being trained in genetic testing during under-
graduate education and with direct involvement in PHG activities.
It seems clear from these findings, therefore, that greater knowledge of genomics and personal-
ized medicine among health professionals not directly involved in genetics would improve the
capacity of health systems to incorporate new genomic technologies [11–14, 35]. Increasing PH
capability in genomics could also help to avoid uncontrolled implementation of technologies with-
out proven benefits, which can lead to inappropriate management of patients, detrimental effects
on patient health, and waste of financial resources [36]. Our results are in line with the findings of
two surveys on the genomics knowledge and attitudes of PH educators conducted respectively in
Italy and the US [22,45], showing that knowledge is a significant predictor of positive attitudes
towards the use of genetic testing and the delivery of genetic services in PH.
Our findings suggest that healthcare professional education could be the first step to
increase knowledge and capacity of professionals on genomics. There are significant differ-
ences in the way in which professional education is delivered across the countries of Europe
and also the study curricula of physicians and non physician PH specialists may differ substan-
tially. A set of core competencies in genomics for health professionals (even though not specifi-
cally addressed at PH professionals) has been proposed by the European Society of Human
Genetics, to provide an appropriate framework for establishing minimum standards of prepa-
ration and guide the development of study curricula for health-care professionals in all Coun-
tries (graduate or post- graduate) [45]. Based on this framework, a study conducted in Italy
tried to identify a set of core competencies in genetics for non-geneticists, both physicians and
non-physicians, developing a proposal of three different curricula according to the profession,
including basic knowledge, but also attitudes and abilities needed to be able to effectively
incorporate genomics into practice. [46]. Given the association observed between a direct
involvement in PHG activities and both knowledge and attitudes, it may be useful to develop
specific training initiatives for the PH workforce in framework of continuous medical educa-
tion and/or on-job training,
This is the first survey conducted at the European level on knowledge and attitudes of PH
professionals relating to genomics, and thus provides useful insights on the topic. However,
despite using several measures to maximise it, the response rate was low and therefore the
results only apply to approximately 10% of the whole EUPHA membership. The low response
rate reflects one of the main challenges of web-based surveys and is coherent with other studies
that also relied on this type of tool. Based on the results of different studies, Ban Mol reported
in fact that a response rate below 10% is not uncommon for web surveys, which have been
shown to generally get a 6 to 15% lower response rate compared to other survey modes [47].
The low response rate in our study was also influenced by our choice not to opt for an “aggres-
sive” approach to reminders: no telephone calls were used, as in our previous surveys, and we
chose to only sent a limited number of reminders (three emails were sent in total to EUPHA
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members), considering that repeated follow-ups have been shown to diminish returns and
may have the counterproductive effect to irritate potential respondents, without noticeably
increasing response rates [48].
A selection bias may therefore have occurred, with respondents differing systematically from
non-respondents. The sample proved to be representative of the population of EUPHA mem-
bers in terms of professional background: a recent survey conducted by the EUPHA secretariat
indicated that 66% of responders identified themselves as researchers, 14% as policymakers and
the remaining 20% as practitioners (data not published), showing a similar distribution than
our sample. However, due to the anonymous nature of the survey, it was not possible to assess
any other difference between responders and non responders. We can assume that people
responding to the survey had, in general, a stronger interest in genomics than non-responders,
and therefore showed more positive attitudes. Given the lower level of knowledge of genomics
among people not involved in this area of work, we can also assume that genomics knowledge
among the European PH community is even lower than reported in our study, reinforcing the
apparent need to increase the genomics capability of professionals not directly dealing with this
area. The fact that our findings are consistent with those of studies conducted in the PH com-
munity in Italy in 2010 and among US public health educators in 2008 [22, 49], and that
responses were obtained from all EU countries, suggests that our conclusions are generally
applicable across European and other nations. Another limitation of the study was the impossi-
bility to compare knowledge and attitudes on genomics across different Countries: respondents
came from a high number of Countries (over 35), not allowing to stratify responses according
to the provenience. The lack of information on the organizational models of genetic services in
all Countries did not allow to control for type of delivery model either [50].
In conclusion, our sample of PH professionals in Europe was positive about incorporating
the increasing number of genomic applications into their working practice, and agreed they
should play a role in this translation process, but their knowledge of PHG is rather weak. Spe-
cific efforts should be made to increase the capacity of PH professionals not directly involved
in genomics, by implementing communication and/or training strategies at national and inter-
national levels. Our findings also highlight an urgent need to further develop and share com-
mon and standardized definitions and operational guidelines on PM within the PH
community in Europe. In this respect, joint research and training initiatives on PM and geno-
mics at the European level, such as the PRECeDI consortium, have proved to be useful in
developing and sharing evidence in this field and should continue to be promoted.
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